|
AU2420897A
(en)
*
|
1996-03-29 |
1997-10-22 |
G.D. Searle & Co. |
Meta-substituted phenylene sulphonamide derivatives
|
|
GB9805655D0
(en)
|
1998-03-16 |
1998-05-13 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
US6521626B1
(en)
|
1998-03-24 |
2003-02-18 |
Celltech R&D Limited |
Thiocarboxamide derivatives
|
|
JP4064059B2
(ja)
|
1998-04-09 |
2008-03-19 |
明治製菓株式会社 |
インテグリンαＶβ３拮抗剤としてのアミノピペリジン誘導体
|
|
GB9814414D0
(en)
|
1998-07-03 |
1998-09-02 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
WO2000006169A1
(en)
*
|
1998-07-29 |
2000-02-10 |
Merck & Co., Inc. |
Integrin receptor antagonists
|
|
GB9821061D0
(en)
|
1998-09-28 |
1998-11-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9826174D0
(en)
|
1998-11-30 |
1999-01-20 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
EP1140194A2
(en)
|
1998-12-23 |
2001-10-10 |
G.D. SEARLE & CO. |
Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia
|
|
US6291503B1
(en)
|
1999-01-15 |
2001-09-18 |
Bayer Aktiengesellschaft |
β-phenylalanine derivatives as integrin antagonists
|
|
US6518283B1
(en)
|
1999-05-28 |
2003-02-11 |
Celltech R&D Limited |
Squaric acid derivatives
|
|
AU6316900A
(en)
|
1999-08-05 |
2001-03-05 |
Meiji Seika Kaisha Ltd. |
Omega-amino-alpha-hydroxycarboxylic acid derivatives having integrin alphavbeta3antagonism
|
|
EP1214293A1
(en)
*
|
1999-09-08 |
2002-06-19 |
Guilford Pharmaceuticals Inc. |
Non-peptidic cyclophilin binding compounds and their use
|
|
EP1088821A1
(en)
*
|
1999-09-28 |
2001-04-04 |
Applied Research Systems ARS Holding N.V. |
Pharmaceutically active sulfonamide derivatives
|
|
US6534513B1
(en)
|
1999-09-29 |
2003-03-18 |
Celltech R&D Limited |
Phenylalkanoic acid derivatives
|
|
WO2001027082A1
(en)
*
|
1999-10-08 |
2001-04-19 |
Meiji Seika Kaisha, Ltd. |
3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN αvβ3 ANTAGONISTS
|
|
US20050059669A1
(en)
*
|
1999-10-08 |
2005-03-17 |
Keiichi Ajito |
M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity
|
|
US6849639B2
(en)
|
1999-12-14 |
2005-02-01 |
Amgen Inc. |
Integrin inhibitors and their methods of use
|
|
US6455539B2
(en)
|
1999-12-23 |
2002-09-24 |
Celltech R&D Limited |
Squaric acid derivates
|
|
JP4039856B2
(ja)
*
|
2000-02-03 |
2008-01-30 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
インテグリン発現阻害剤
|
|
ATE375330T1
(de)
|
2000-04-17 |
2007-10-15 |
Ucb Pharma Sa |
Enamin-derivate als zell-adhäsionsmoleküle
|
|
US6545013B2
(en)
|
2000-05-30 |
2003-04-08 |
Celltech R&D Limited |
2,7-naphthyridine derivatives
|
|
US6403608B1
(en)
|
2000-05-30 |
2002-06-11 |
Celltech R&D, Ltd. |
3-Substituted isoquinolin-1-yl derivatives
|
|
JP2004502762A
(ja)
|
2000-07-07 |
2004-01-29 |
セルテック アール アンド ディ リミテッド |
二環性ヘテロ芳香環を含有するインテグリンアンタゴニストとしてのスクエア酸誘導体
|
|
WO2002010136A1
(en)
|
2000-08-02 |
2002-02-07 |
Celltech R & D Limited |
3-substituted isoquinolin-1-yl derivatives
|
|
CA2435829A1
(en)
|
2001-01-25 |
2002-08-01 |
Guilford Pharmaceuticals Inc. |
Trisubstituted carbocyclic cyclophilin binding compounds and their use
|
|
ATE350660T1
(de)
*
|
2001-02-21 |
2007-01-15 |
Eisai Co Ltd |
Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression
|
|
US6710061B2
(en)
*
|
2001-03-09 |
2004-03-23 |
Ortho-Mcneil Pharamceutical, Inc. |
Aminopyrrolidine sulfonamides as serine protease inhibitors
|
|
GB0127615D0
(en)
*
|
2001-07-09 |
2002-01-09 |
Aventis Pharm Prod Inc |
Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
|
|
KR20100054884A
(ko)
|
2001-10-22 |
2010-05-25 |
더 스크립스 리서치 인스티튜트 |
항체 표적화 화합물
|
|
WO2003059872A1
(en)
*
|
2001-12-31 |
2003-07-24 |
Bayer Pharmaceuticals Corporation |
Avb3 and avb5 integrin antagonists and methods of treating diseases or conditions associated with avb3 and avb5 integrins
|
|
WO2003075957A1
(en)
*
|
2002-03-04 |
2003-09-18 |
Medimmune, Inc. |
The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
|
|
WO2003075741A2
(en)
*
|
2002-03-04 |
2003-09-18 |
Medimmune, Inc. |
METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
|
|
WO2004066956A2
(en)
*
|
2003-01-30 |
2004-08-12 |
Medimmune, Inc. |
Uses of integrin alphavbeta3 antagonists
|
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
|
WO2007022964A2
(de)
|
2005-08-24 |
2007-03-01 |
Abbott Gmbh & Co. Kg |
Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
|
|
CA2630415A1
(en)
*
|
2005-10-20 |
2007-04-26 |
The Scripps Research Institute |
Fc labeling for immunostaining and immunotargeting
|
|
EP2489656A1
(en)
|
2007-12-21 |
2012-08-22 |
Ligand Pharmaceuticals Inc. |
Selective androgen receptor modulators (sarms) and uses thereof
|
|
US8518927B2
(en)
|
2009-02-10 |
2013-08-27 |
The Scripps Research Institute |
Chemically programmed vaccination
|
|
US10328082B2
(en)
|
2014-05-30 |
2019-06-25 |
Pfizer Inc. |
Methods of use and combinations
|
|
AU2020257397A1
(en)
|
2019-04-19 |
2021-12-16 |
Ligand Pharmaceuticals Inc. |
Crystalline forms and methods of producing crystalline forms of a compound
|
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|